These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 5165541)
1. Microbial contamination of nonsterile antibiotic market samples: a survey. Bowman FW; White M; Lyles RL J Pharm Sci; 1971 Jul; 60(7):1099-101. PubMed ID: 5165541 [No Abstract] [Full Text] [Related]
2. Bacterial contamination in some nonsterile antibiotic drugs. White M; Bowman FW; Kirshbaum A J Pharm Sci; 1968 Jun; 57(6):1061-3. PubMed ID: 4876451 [No Abstract] [Full Text] [Related]
3. Microbial identification strategies in the pharmaceutical industry. Cundell AM PDA J Pharm Sci Technol; 2006; 60(2):111-23. PubMed ID: 16696194 [TBL] [Abstract][Full Text] [Related]
4. How the pharmaceutical industry brings an antibiotic drug to market in the United States. Billstein SA Antimicrob Agents Chemother; 1994 Dec; 38(12):2679-82. PubMed ID: 7695247 [No Abstract] [Full Text] [Related]
5. Viability-based rapid microbiological methods for sterility testing and the need for identification of contamination. Moldenhauer J PDA J Pharm Sci Technol; 2006; 60(2):81-8. PubMed ID: 16696190 [No Abstract] [Full Text] [Related]
7. [Microbial contamination of drugs--Ecology and antibiotic resistance. Part II (author's transl)]. Devleeschouwer MJ; Akin A; Dony J J Pharm Belg; 1980; 35(4):266-72. PubMed ID: 7441475 [No Abstract] [Full Text] [Related]
8. Microbial contamination of syringes during preparation: the direct influence of environmental cleanliness and risk manipulations on end-product quality. Stucki C; Sautter AM; Favet J; Bonnabry P Am J Health Syst Pharm; 2009 Nov; 66(22):2032-6. PubMed ID: 19890087 [TBL] [Abstract][Full Text] [Related]
10. Charting and Evaluation of Environmental Microbial Monitoring Data. Bar R PDA J Pharm Sci Technol; 2015; 69(6):743-61. PubMed ID: 26659105 [TBL] [Abstract][Full Text] [Related]
11. [Dynamics of populations of microbial antagonists in nonsterile soil]. Polianskaia LM; Kozhevin PA; Zviagintsev DG Mikrobiologiia; 1983; 52(1):145-8. PubMed ID: 6843384 [TBL] [Abstract][Full Text] [Related]
12. ICH Q7A; 4.40 containment of beta-lactam antibiotics: an industry perspective. Kasai T; Okubo T; Yamanaka A; Takahira M; Takeuchi M; Nakamura K PDA J Pharm Sci Technol; 2002; 56(6):312-7. PubMed ID: 12497768 [TBL] [Abstract][Full Text] [Related]
13. [Microbial contamination of some non-injection drug preparations]. Berezovskaia IV Farmatsiia; 1976; 25(2):74-8. PubMed ID: 1269795 [No Abstract] [Full Text] [Related]
14. Is the GAIN Act a turning point in new antibiotic discovery? Brown ED Can J Microbiol; 2013 Mar; 59(3):153-6. PubMed ID: 23540332 [TBL] [Abstract][Full Text] [Related]
18. Efforts to support the development of fusidic acid in the United States. Fernandes P; Pereira D Clin Infect Dis; 2011 Jun; 52 Suppl 7():S542-6. PubMed ID: 21546632 [TBL] [Abstract][Full Text] [Related]
19. This is medical progress? Trends and consequences of antibiotic use in the United States. Simmons HE; Stolley PD JAMA; 1974 Mar; 227(9):1023-8. PubMed ID: 4405926 [No Abstract] [Full Text] [Related]
20. Quality Control: microbial limit tests for nonsterile pharmaceuticals, part 2. Vu N; Lou JR; Kupiec TC Int J Pharm Compd; 2014; 18(4):305-10. PubMed ID: 25474859 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]